A phase I study assessing safety and tolerability of a DNA vaccine [herpes simplex virus DNA vaccine] with a DNA encoded immunostimulator, administered by particle mediated epidermal delivery using the PowderMed ND10 delivery system in HSV [herpes simplex virus]-2 seronegative healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2008
At a glance
- Drugs Herpes simplex virus DNA vaccine (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions
- 20 Nov 2008 Status changed from active, no longer recruiting to completed.
- 06 Nov 2006 New trial record.